Ascendis Pharma A/S（ASND）财务数据ASNDAscendis Pharma A/S

Ascendis Pharma A/S (ASND) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Commercial sale of products, accounting for 92.8% of total sales, equivalent to €314.91M. Other significant revenue streams include Milestones and Sale of clinical supply. Understanding this composition is critical for investors evaluating how ASND navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, Ascendis Pharma A/S maintains a gross margin of 91.85%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 64.98%, while the net margin is 61.00%. These profitability ratios, combined with a Return on Equity (ROE) of 118.78%, provide a clear picture of how effectively ASND converts its operational activities into shareholder value.

In the context of the broader market, ASND competes directly with industry leaders such as EXEL and JAZZ. With a market capitalization of $16.13B, it holds a leading position in the sector. When comparing efficiency, ASND's gross margin of 91.85% stands against EXEL's 96.71% and JAZZ's 76.30%. Such benchmarking helps identify whether Ascendis Pharma A/S is trading at a premium or discount relative to its financial performance.

Ascendis Pharma has shown a strong recovery in its financials, with a net income of €207 million in Q2 2026 compared to a loss of €39 million a year prior. The gross margin remains robust at 91.85%, indicating efficient cost management and profitability potential.